#biopharmaceutical - Techseriesinsight

May 26, 2025
PRNewswire
Biotechnology

Dizal to Highlight its Portfolio Advances in Hematologic Malignancies and Lung Cancer at ASCO 2025

Dizal (SSE:688192), a biopharmaceutical company committed to developing novel medicines for the treatment of cancer and immunological diseases, announced today that it will present latest clinical study results of...

May 15, 2025
PRNewswire
Biotechnology

Dizal to Present Promising Clinical Data on Golidocitinib and DZD8586 for the Treatment of Lymphoma at the Coming International Hematology Conferences

Dizal (SSE:688192), a biopharmaceutical company committed to developing novel medicines for the treatment of cancer and immunological diseases, announced that the latest data from eight hematologic malignancy clinical trials...

May 13, 2025
PRNewswire
Cloud

Rockwell Automation Launches PharmaSuite 12.00 to Accelerate Secure, Scalable Deployments

Rockwell Automation, Inc. (NYSE: ROK), the world’s largest company dedicated to industrial automation and digital transformation, today announced the launch of FactoryTalk® PharmaSuite® 12.00. The latest release of its manufacturing execution system...

May 9, 2025
PRNewswire
Biotechnology

IASO Bio Receives Orphan Drug Designation from the Saudi Food and Drug Authority for Equecabtagene Autoleucel

IASO Biotherapeutics (“IASO Bio”), a biopharmaceutical company focused on the discovery, development, manufacturing, and commercialization of innovative cell therapies and biologics, today announced that its self-developed BCMA-targeted CAR-T cell...

May 9, 2025
PRNewswire
Biotechnology

Minghui Pharmaceutical Announces Strategic Partnership and Licensing Agreement with Qilu Pharmaceutical to Develop B7-H3 ADC in Greater China

Minghui Pharmaceutical (“Minghui”), a late-stage clinical biopharmaceutical company, today announced an exclusive licensing and collaboration agreement with Qilu Pharmaceutical (“Qilu”) for the development, manufacturing, and commercialization of its B7-H3...

May 6, 2025
PRNewswire
Biotechnology

Galmed Announces First Time Results in Oncology Studies: Aramchol Significantly Enhances Bayer’s Regorafenib Effect in GI Cancer Models

Galmed Pharmaceuticals Ltd. (NASDAQ: GLMD) (“Galmed” or the “Company”), a clinical-stage biopharmaceutical company for cardiometabolic diseases and GI oncological therapeutics, announced today that the first set of oncology studies has...

May 1, 2025
PRNewswire
Biotechnology

Dynavax Announces Nationwide Harris Poll Survey Results Finding Americans Underestimate the Serious Consequences of Hepatitis B and Vaccine Protection Benefits

Dynavax Technologies Corporation (Nasdaq: DVAX), a commercial stage biopharmaceutical company developing and commercializing innovative vaccines, today announced the results of the Hepatitis B Perceptions and Insights Survey conducted by The Harris Poll, which...

April 29, 2025
PRNewswire
Biotechnology

Lutris Pharma Announces the Appointment of Seasoned Life Science Executive, Sumant Ramachandra, M.D., Ph.D., as Chief Executive Officer

Lutris Pharma, a clinical stage biopharmaceutical company focused on improving anti-cancer therapies by reducing cutaneous dose limiting toxicity, today announced that, effective April 20, 2025, the Board of Directors has appointed Sumant Ramachandra, M.D., Ph.D. as Chief...

April 22, 2025
PRNewswire
Healthcare

Angel MedFlight Earns Fourth Consecutive NAAMTA Global Accreditation

NAAMTA Global and Angel MedFlight are pleased to announce the renewal of Angel MedFlight’s accreditation for a fourth consecutive three-year term. This reaccreditation reflects Angel MedFlight’s consistent adherence to the highest standards...

April 17, 2025
PRNewswire
Healthcare

Palatin Reports Positive Appetite Suppression Results From Phase 2 Obesity Study of MC4R Agonist Bremelanotide and Tirzepatide

Palatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor system, announced positive appetite suppression results...